Clinical trials: AMD
Age-Related Macular Degeneration
IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
This is a prospective, single-blind, randomized study to evaluate intravitreal aflibercept injection (IAI) versus sham as prophylaxis against conversion to neovascular age-related macular degeneration (AMD) in "high-risk"…
- Trial name
- PRO-CON (NCT02462889)
- Testing
- Intravitreal aflibercept injection
- Where
- 4 sites in United States
- Volunteers
- 128 people
- Sponsor
- Jeffrey S Heier
Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
- Trial name
- Camellia (NCT01976312)
- Testing
- Ranibizumab 0.5 mg
- Where
- 34 sites in China, Hong Kong and 5 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Wet Age-related Macular Degeneration
Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration
This study will evaluate the therapeutic effects and safety of 800 mg ALK4290 administered daily over a 6-week dosing period in newly diagnosed patients with wet age-related macular degeneration (wAMD).
- Trial name
- NCT03558061
- Testing
- ALK4290
- Where
- 5 sites in Hungary
- Volunteers
- 30 people
- Sponsor
- Alkahest, Inc.
Age-related Macular Degeneration
Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration
This study is to investigate the protective effects of supplemental lutein and zeaxanthin on early age-related macular degeneration (AMD) patients in China.
- Trial name
- NCT01528605
- Testing
- low lutein, high lutein, lutein plus zeaxanthin
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Peking University
Age Related Macular Degeneration
Study for Recalcitrant Age Related Macular Degeneration
50 Patients with recalcitrant exudative age-related macular degeneration with a history of retinal or subretinal fluid after multiple intravitreal injections with ranibizumab 0.5mg and subsequently treated with ranibizumab 2.0mg…
- Trial name
- TURF (NCT01543568)
- Testing
- aflibercept 2.0 mg
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- David M. Brown, M.D.
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Ischemia, Vitelliform Macular Dystrophy
Sildenafil for Treatment of Choroidal Ischemia
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and…
- Conditions
- Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy
- Trial name
- NCT04356716
- Testing
- Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Columbia University
Visual Acuity, Geographic Atrophy
A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy
The purpose of this study is to evaluate the safety and performance profile of the suprachoroidal surgical approach and the Delivery System.
- Conditions
- Visual Acuity, Geographic Atrophy, Macular Degeneration
- Trial name
- PRELUDE (NCT02659098)
- Testing
- CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Janssen Research & Development, LLC
Choroid Neovascularization, Age-Related Macular Degeneration
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
- Trial name
- NCT00395057
- Testing
- AGN 211745, Ranibizumab 500µg
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 138 people
- Sponsor
- Allergan
Pompe Disease
Extension Study for Patients Who Have Participated in a BMN 701 Study
This is a Phase 2 open-label, multiple dose study of BMN 701 administered by IV infusion every 2 weeks (qow) to patients with late-onset Pompe disease.
- Trial name
- NCT01435772
- Testing
- BMN 701
- Where
- 12 sites in United States, Australia and 4 more
- Volunteers
- 21 people
- Sponsor
- BioMarin Pharmaceutical
Age-Related Macular Degeneration, Diabetic Retinopathy
Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations
In this study, participants will be imaged using two Optical Coherence Tomography (OCT) devices: device N, a standard conventional OCT device with an invention (comfortable chin and forehead rest that can be adjusted to fit each…
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Central Serous Chorioretinopathy, Glaucoma
- Trial name
- NCT05686421
- Testing
- OCT Imaging Using Device N, OCT Imaging Using Device C
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- NCT03823287
- Testing
- Faricimab, Aflibercept
- Where
- 161 sites in United States, Canada and 13 more
- Volunteers
- 671 people
- Sponsor
- Hoffmann-La Roche
Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration
Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Background: Age-related macular degeneration (AMD) is an eye disease. It is the leading cause of vision loss in people over 55 in the U.S. Changes in the eye can make it difficult for they eye to adjust to low light.
- Trial name
- NCT03478878
- Testing
- Vitamin A Palmitate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Eye Institute (NEI)
Age-related Macular Degeneration (AMD)
Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
The purpose of this study is to determine the efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration.
- Trial name
- COLUMBUS-AMD (NCT02611778)
- Testing
- ranibizumab
- Where
- 58 sites in Austria, Czechia and 10 more
- Volunteers
- 712 people
- Sponsor
- Bioeq GmbH